Literature DB >> 26974887

Human influenza viruses and CD8(+) T cell responses.

Emma J Grant1, Sergio M Quiñones-Parra1, E Bridie Clemens1, Katherine Kedzierska2.   

Abstract

Influenza A viruses (IAVs) cause significant morbidity and mortality worldwide, despite new strain-specific vaccines being available annually. As IAV-specific CD8(+) T cells promote viral control in the absence of neutralizing antibodies, and can mediate cross-reactive immunity toward distinct IAVs to drive rapid recovery from both mild and severe influenza disease, there is great interest in developing a universal T cell vaccine. However, despite detailed studies in mouse models of influenza virus infection, there is still a paucity of data on human epitope-specific CD8(+) T cell responses to IAVs. This review focuses on our current understanding of human CD8(+) T cell immunity against distinct IAVs and discusses the possibility of achieving a CD8(+) T cell mediated-vaccine that protects against multiple, distinct IAV strains across diverse human populations. We also review the importance of CD8(+) T cell immunity in individuals highly susceptible to severe influenza infection, including those hospitalised with influenza, the elderly and Indigenous populations.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26974887     DOI: 10.1016/j.coviro.2016.01.016

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  41 in total

1.  Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells.

Authors:  Frances C Knight; Pavlo Gilchuk; Amrendra Kumar; Kyle W Becker; Sema Sevimli; Max E Jacobson; Naveenchandra Suryadevara; Lihong Wang-Bishop; Kelli L Boyd; James E Crowe; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2019-10-04       Impact factor: 15.881

2.  Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison.

Authors:  Arun Kumar; Janet E McElhaney; Lisa Walrond; Terry D Cyr; Shahzma Merani; Tobias R Kollmann; Scott A Halperin; David W Scheifele
Journal:  Hum Vaccin Immunother       Date:  2017-06-21       Impact factor: 3.452

Review 3.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine.

Authors:  Florian Krammer; Adolfo García-Sastre; Peter Palese
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

4.  Antigenic Restimulation of Virus-Specific Memory CD8+ T Cells Requires Days of Lytic Protein Accumulation for Maximal Cytotoxic Capacity.

Authors:  Stephen A Migueles; Daniel C Rogan; Noah V Gavil; Elizabeth P Kelly; Sushila A Toulmin; Lawrence T Wang; Justin Lack; Addison J Ward; Patrick F Pryal; Amanda K Ludwig; Renata G Medina; Benjamin J Apple; Christina N Toumanios; April L Poole; Catherine A Rehm; Sara E Jones; C Jason Liang; Mark Connors
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

Review 5.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

6.  The cellular and humoral immune response to influenza vaccination is comparable in asthmatic and healthy subjects.

Authors:  Andrea Aida Velasco-Medina; Miguel Leonardo García-León; Guillermo Velázquez-Sámano; Rosa María Wong-Chew
Journal:  Hum Vaccin Immunother       Date:  2020-05-21       Impact factor: 3.452

7.  Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection.

Authors:  David Groeger; Elisa Schiavi; Ray Grant; Magdalena Kurnik-Łucka; David Michalovich; Rick Williamson; Soren Beinke; Barry Kiely; Cezmi A Akdis; Edith M Hessel; Fergus Shanahan; Liam O' Mahony
Journal:  EBioMedicine       Date:  2020-09-11       Impact factor: 8.143

8.  Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection.

Authors:  Li-Meng Yan; Olive T W Li; Chek M Poh; Ranawaka A P M Perera; Sophie A Valkenburg; Malik Peiris; Leo L M Poon
Journal:  Virology       Date:  2018-09-21       Impact factor: 3.616

9.  The humanized DRAGA mouse (HLA-A2. HLA-DR4. RAG1 KO. IL-2R g c KO. NOD) establishes inducible and transmissible models for influenza type A infections.

Authors:  Mirian Mendoza; Devi Gunasekera; Kathleen P Pratt; Qi Qiu; Sofia Casares; Teodor-D Brumeanu
Journal:  Hum Vaccin Immunother       Date:  2020-03-04       Impact factor: 3.452

10.  Hypercapnia Suppresses Macrophage Antiviral Activity and Increases Mortality of Influenza A Infection via Akt1.

Authors:  S Marina Casalino-Matsuda; Fei Chen; Francisco J Gonzalez-Gonzalez; Aisha Nair; Sandra Dib; Alex Yemelyanov; Khalilah L Gates; G R Scott Budinger; Greg J Beitel; Peter H S Sporn
Journal:  J Immunol       Date:  2020-06-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.